Literature DB >> 31256218

Aplastic anemia associated with Crohn's disease: a tertiary center retrospective study.

Song Su1, ZhenZhen Liu1, Fang Wang2, YuJie Zhang1, Yi Chu1, MingZuo Jiang1, Bing Xu3, Nan Wu4, JunChao Lin5, XianMin Xue1, YongQuan Shi1, Shaoqi Yang6, KaiChun Wu7, Jie Liang8.   

Abstract

Aplastic anemia (AA) has been reported to be associated with inflammatory bowel disease (IBD), but mostly with ulcerative colitis (UC). Little is known about the associations between AA and Crohn's disease (CD). We aim to determine the portraits of patients with AA-CD. Among a total of 657 patients with CD registered in Xijing Hospital of Digestive Diseases IBD center from January 2008 to October 2018, the patients diagnosed with concurrent AA were reviewed. Clinical presentation, medical history, endoscopic features, response to treatment, and prognosis in this set of patients were collected. Six male patients confirmed as CD associated with AA were identified. The incidence rate was 0.91% for CD associated with AA in our series. Average age at diagnosis of CD and AA was 41.5 and 39.2 years old, respectively. Abdominal pain and hyperpyrexia were the most common symptoms. Endoscopic findings showed discontinued severe inflammation, and all these patients presented with deformed ileocecal valve. Conventional pharmacotherapy failed to achieve a favorable effect. Four of six patients died from CD progression and its complications. None of these patients received bone marrow transplantation treatment because of poverty. Concurrence of AA and CD is a relatively rare condition. Immunologic impairment may play an important pathogenic role and deserves further attention. Males are more susceptible to this condition. Patients with AA-CD are prone to a severe clinical course and poor prognosis. Conventional therapy achieves no potent effect, and allogeneic stem cell transplantation may be a potentially efficient therapy.

Entities:  

Keywords:  Aplastic anemia; Crohn’s disease; Incidence; Stem cell transplantation

Mesh:

Year:  2019        PMID: 31256218     DOI: 10.1007/s00277-019-03729-4

Source DB:  PubMed          Journal:  Ann Hematol        ISSN: 0939-5555            Impact factor:   3.673


  1 in total

1.  Myeloid lineage enhancers drive oncogene synergy in CEBPA/CSF3R mutant acute myeloid leukemia.

Authors:  Theodore P Braun; Mariam Okhovat; Cody Coblentz; Sarah A Carratt; Amy Foley; Zachary Schonrock; Brittany M Curtiss; Kimberly Nevonen; Brett Davis; Brianna Garcia; Dorian LaTocha; Benjamin R Weeder; Michal R Grzadkowski; Joey C Estabrook; Hannah G Manning; Kevin Watanabe-Smith; Sophia Jeng; Jenny L Smith; Amanda R Leonti; Rhonda E Ries; Shannon McWeeney; Cristina Di Genua; Roy Drissen; Claus Nerlov; Soheil Meshinchi; Lucia Carbone; Brian J Druker; Julia E Maxson
Journal:  Nat Commun       Date:  2019-11-29       Impact factor: 17.694

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.